广济药业拟定增不超过6亿元 优化公司资本结构

Core Viewpoint - Hubei Guangji Pharmaceutical Co., Ltd. plans to raise up to 600 million yuan through a private placement of shares to its controlling shareholder, Yangtze Industry Investment Group, at a price of 6.32 yuan per share, with the funds primarily aimed at repaying loans and supplementing working capital to optimize its capital structure and reduce its debt ratio [1][2]. Group 1 - The capital increase will help Guangji Pharmaceutical optimize its capital structure and enhance its risk resistance capability, as the company's debt-to-asset ratio was 62.67% as of September 30, 2025, indicating a high cost of debt financing [1]. - The funds raised will increase the total assets and net assets of Guangji Pharmaceutical, thereby strengthening its financial position and supporting sustainable development [1]. Group 2 - The capital increase will stabilize the equity structure of Guangji Pharmaceutical and enhance control stability, as Yangtze Industry Group holds 25.26% of the company's shares, reinforcing its position as the controlling shareholder [2]. - The full subscription of the new shares by the controlling shareholder sends a positive signal to the market, reflecting confidence in the company's future development and potentially boosting investor sentiment and the company's investment value [2].